China-based Sichuan Kelun-Biotech Biopharmaceutical Co Ltd announced on Monday that the company has been granted investigational new drug (IND) clearance to initiate the clinical study of its potential first-in-class innovative antibody drug conjugate (ADC), SKB518, from the US Food and Drug Administration (FDA).
In June 2024, the company received a clinical trial notice approving the IND application for SKB518 for advanced solid tumours from Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA). The Phase 1 clinical trial for SKB518 is ongoing in China.
Developed by Kelun-Biotech, SKB518 is a novel ADC drug with potential first-in-class target and proprietary intellectual property rights based on the biological characteristics of the target and using the technology of the OptiDCTM platform. It has demonstrated promising efficacy and safety in preclinical studies and is intended to be used for the treatment of advanced solid tumours.
Pykus Therapeutics' PYK-2101 achieves positive interim clinical trial results
FDA accepts Novo Nordisk's filing application for oral semaglutide 25 mg
Nutshell Therapeutics' NTS071 p53 allosteric reactivator cleared for US clinical trial
Blue Earth Therapeutics initiates Phase 2 trial in metastatic castrate resistant prostate cancer
Armata Pharmaceuticals' AP-SA02 clinical trial receives additional US DoD funding
BioArctic receives SEK101.7m in royalties from Q1 Leqembi sales
SKNV launches Kefunova Cream for actinic keratosis and superficial basal cell carcinoma
Ingenium Therapeutics' Gengleucel to enter Phase 2 trial in MRD+ AML following FDA feedback
Nuformix receives positive EMA opinion for orphan drug designation of NXP002 in IPF
MHRA to review monthly maintenance dosing for Leqembi in early Alzheimer's treatment
Ro integrates with NovoCare Pharmacy to offer access to all doses of Wegovy at lowest price
Myosin Therapeutics receives grant to advance MT-110 clinical trial in methamphetamine use disorder
CSL Vifor and Travere Therapeutics gain full EU approval for FILSPARI in IgA nephropathy